-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The discovery, production and use of antibacterial drugs is a huge advancement in human medicine, saving a large number of patients
.
With the increase in the abuse of antibacterial drugs and the increase in bacterial resistance, the "National Action Plan for Containing Antimicrobial Resistance (2016-2020)" formulated by China has restricted the market space for generic drugs and reserved market space for the development of innovative antibacterial drugs
.
For example, under the strong support of national policies, in June 2021, the domestically developed next-generation oxazolidinone new antibacterial drug developed by Mengke Pharmaceutical passed the priority review and approval procedure of the National Food and Drug Administration and was approved for marketing, and it will be fully launched.
Commercialization in China
.
It is reported that compared with existing drugs, contizolamide not only guarantees excellent efficacy against multi-drug-resistant gram-positive bacteria, but also improves drug safety and provides doctors and patients with safer medication options and more A good medication plan, Contizolamide has the potential to replace the current similar antibacterial drugs, and is expected to become the first clinical choice for anti-multidrug-resistant Gram-positive bacteria
.
In addition, data shows that only one new class 1 antibacterial drug for systemic use was approved each year from 2016 to 2017, but five have been approved so far in 2021
.
Among them, on December 16, Zai Lab's two new class 1 drugs, omacycline tosylate tablets and omacycline tosylate for injection, were approved for marketing, becoming the 4th and 5th systemic antibacterial approved this year.
Innovative medicine
.
According to data, omacycline tosylate is a new type of tetracycline, specifically designed to overcome the resistance of tetracycline and improve the activity against a broad spectrum of bacterial infections
.
The data also shows that since 2021, there have been 3 systemic antibacterial Class 1 new drugs that have been clinically approved and approved, two of which are biologics Class 1 new drugs
.
The industry said that with the continuous improvement of domestic research and development technology, China's antibacterial drug field is about to usher in bio-innovative drugs
.
In addition, the priority review system has also speeded up the listing of innovative drugs, and the dynamic adjustment of the medical insurance catalog has greatly accelerated the time for new drugs to enter medical insurance after approval
.
For example, the two new class 1 antibacterial drugs approved for systemic use only took less than half a year from listing to successful entry into the medical insurance catalog.
This shows the strength of the national level of support for innovative drugs.
.
The data shows that the sales of Class 1 new drugs in the field of systemic antibacterial drugs that have successfully entered the medical insurance catalogue are also moving
.
For example, after the new generation of nitroimidazole antibacterial drug Morpholinidazole Sodium Chloride Injection entered the negotiation catalogue in 2017, the sales growth rate of Hausen Pharmaceuticals was as high as 2158.
82%, and the growth rate in 2018 also exceeded 1000%.
; In 2019, the drug became a new "billion-level" variety; in 2020, it achieved over 400 million yuan; sales in the first half of 2021 have exceeded that of the entire year of 2019, continuing to maintain a rapid growth trend
.
It is understood that in the 2021 version of the National Medical Insurance Routine List, 10 major varieties of systemic antibacterial drugs have already entered some dosage forms
.
The industry said that medical insurance limits the scope of use of some antibiotics, which can not only reduce unnecessary expenditures for patients, but also prevent antibiotics from being abused and causing drug resistance
.
At the same time, the medical insurance catalogue has also given significant support to innovative drugs.
The rapid increase in volume of innovative drugs in the market will also promote new and more changes in the market structure of systemic antibacterial drugs
.
.
With the increase in the abuse of antibacterial drugs and the increase in bacterial resistance, the "National Action Plan for Containing Antimicrobial Resistance (2016-2020)" formulated by China has restricted the market space for generic drugs and reserved market space for the development of innovative antibacterial drugs
.
For example, under the strong support of national policies, in June 2021, the domestically developed next-generation oxazolidinone new antibacterial drug developed by Mengke Pharmaceutical passed the priority review and approval procedure of the National Food and Drug Administration and was approved for marketing, and it will be fully launched.
Commercialization in China
.
It is reported that compared with existing drugs, contizolamide not only guarantees excellent efficacy against multi-drug-resistant gram-positive bacteria, but also improves drug safety and provides doctors and patients with safer medication options and more A good medication plan, Contizolamide has the potential to replace the current similar antibacterial drugs, and is expected to become the first clinical choice for anti-multidrug-resistant Gram-positive bacteria
.
In addition, data shows that only one new class 1 antibacterial drug for systemic use was approved each year from 2016 to 2017, but five have been approved so far in 2021
.
Among them, on December 16, Zai Lab's two new class 1 drugs, omacycline tosylate tablets and omacycline tosylate for injection, were approved for marketing, becoming the 4th and 5th systemic antibacterial approved this year.
Innovative medicine
.
According to data, omacycline tosylate is a new type of tetracycline, specifically designed to overcome the resistance of tetracycline and improve the activity against a broad spectrum of bacterial infections
.
The data also shows that since 2021, there have been 3 systemic antibacterial Class 1 new drugs that have been clinically approved and approved, two of which are biologics Class 1 new drugs
.
The industry said that with the continuous improvement of domestic research and development technology, China's antibacterial drug field is about to usher in bio-innovative drugs
.
In addition, the priority review system has also speeded up the listing of innovative drugs, and the dynamic adjustment of the medical insurance catalog has greatly accelerated the time for new drugs to enter medical insurance after approval
.
For example, the two new class 1 antibacterial drugs approved for systemic use only took less than half a year from listing to successful entry into the medical insurance catalog.
This shows the strength of the national level of support for innovative drugs.
.
The data shows that the sales of Class 1 new drugs in the field of systemic antibacterial drugs that have successfully entered the medical insurance catalogue are also moving
.
For example, after the new generation of nitroimidazole antibacterial drug Morpholinidazole Sodium Chloride Injection entered the negotiation catalogue in 2017, the sales growth rate of Hausen Pharmaceuticals was as high as 2158.
82%, and the growth rate in 2018 also exceeded 1000%.
; In 2019, the drug became a new "billion-level" variety; in 2020, it achieved over 400 million yuan; sales in the first half of 2021 have exceeded that of the entire year of 2019, continuing to maintain a rapid growth trend
.
It is understood that in the 2021 version of the National Medical Insurance Routine List, 10 major varieties of systemic antibacterial drugs have already entered some dosage forms
.
The industry said that medical insurance limits the scope of use of some antibiotics, which can not only reduce unnecessary expenditures for patients, but also prevent antibiotics from being abused and causing drug resistance
.
At the same time, the medical insurance catalogue has also given significant support to innovative drugs.
The rapid increase in volume of innovative drugs in the market will also promote new and more changes in the market structure of systemic antibacterial drugs
.
